Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Review

Advancing stem cell therapy from bench to bedside: lessons from drug therapies

Authors: Thekkeparambil Chandrabose Srijaya, Thamil Selvee Ramasamy, Noor Hayaty Abu Kasim

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

The inadequacy of existing therapeutic tools together with the paucity of organ donors have always led medical researchers to innovate the current treatment methods or to discover new ways to cure disease. Emergence of cell-based therapies has provided a new framework through which it has given the human world a new hope. Though relatively a new concept, the pace of advancement clearly reveals the significant role that stem cells will ultimately play in the near future. However, there are numerous uncertainties that are prevailing against the present setting of clinical trials related to stem cells: like the best route of cell administration, appropriate dosage, duration and several other applications. A better knowledge of these factors can substantially improve the effectiveness of disease cure or organ repair using this latest therapeutic tool. From a certain perspective, it could be argued that by considering certain proven clinical concepts and experience from synthetic drug system, we could improve the overall efficacy of cell-based therapies. In the past, studies on synthetic drug therapies and their clinical trials have shown that all the aforementioned factors have critical ascendancy over its therapeutic outcomes. Therefore, based on the knowledge gained from synthetic drug delivery systems, we hypothesize that by employing many of the clinical approaches from synthetic drug therapies to this new regenerative therapeutic tool, the efficacy of stem cell-based therapies can also be improved.
Appendix
Available only for authorised users
Literature
2.
go back to reference Picanc¸o-Castro V, Moreira LF, Kashima S, Covas DT: Can pluripotent stem cells be used in cell-based therapy?. Cell Reprogram. 2014, 16 (2): 98-107. Picanc¸o-Castro V, Moreira LF, Kashima S, Covas DT: Can pluripotent stem cells be used in cell-based therapy?. Cell Reprogram. 2014, 16 (2): 98-107.
3.
go back to reference Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968, 2: 1366-1369.PubMed Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968, 2: 1366-1369.PubMed
4.
go back to reference Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999, 5: 309-313.PubMed Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999, 5: 309-313.PubMed
5.
go back to reference Syková E, Homola A, Mazanec R, Lachmann H, Konrádová SL, Kobylka P, Pádr R, Neuwirth J, Komrska V, Vávra V, Stulík J, Bojar M: Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 2006, 15 (Suppl 8–9): 675-687.PubMed Syková E, Homola A, Mazanec R, Lachmann H, Konrádová SL, Kobylka P, Pádr R, Neuwirth J, Komrska V, Vávra V, Stulík J, Bojar M: Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 2006, 15 (Suppl 8–9): 675-687.PubMed
6.
go back to reference Savitz SI, Misra V, Kasam M, Juneja H, Cox CS, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC: Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011, 70 (Suppl 1): 59-69.PubMed Savitz SI, Misra V, Kasam M, Juneja H, Cox CS, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC: Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011, 70 (Suppl 1): 59-69.PubMed
7.
go back to reference Takami T, Terai S, Sakaida I: Advanced therapies using autologous bone marrow cells for chronic liver disease. Discov Med. 2012, 14 (Suppl 74): 7-12.PubMed Takami T, Terai S, Sakaida I: Advanced therapies using autologous bone marrow cells for chronic liver disease. Discov Med. 2012, 14 (Suppl 74): 7-12.PubMed
8.
go back to reference Trounson A, Thakar RG, Lomax G, Gibbons D: Clinical trials for stem cell therapies. BMC Med. 2011, 9: 46-52. Trounson A, Thakar RG, Lomax G, Gibbons D: Clinical trials for stem cell therapies. BMC Med. 2011, 9: 46-52.
9.
go back to reference Sagar J, Chaib B, Sales K, Winslet M, Seifalian A: Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int. 2007, 7: 9-PubMedCentralPubMed Sagar J, Chaib B, Sales K, Winslet M, Seifalian A: Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int. 2007, 7: 9-PubMedCentralPubMed
10.
go back to reference Sales KM, Winslet MC, Seifalian AM: Stem cells and cancer: an overview. Stem Cell Rev. 2007, 3: 249-255.PubMed Sales KM, Winslet MC, Seifalian AM: Stem cells and cancer: an overview. Stem Cell Rev. 2007, 3: 249-255.PubMed
11.
go back to reference Hess DC, Borlongan CV: Stem cells and neurological diseases. Cell Prolif. 2008, 41: 94-114.PubMed Hess DC, Borlongan CV: Stem cells and neurological diseases. Cell Prolif. 2008, 41: 94-114.PubMed
12.
go back to reference Van Laar JM, Tyndall A: Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford). 2006, 45: 1187-1193. Van Laar JM, Tyndall A: Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford). 2006, 45: 1187-1193.
13.
go back to reference Pellegrini G, De Luca M, Arsenijevic Y: Towards therapeutic application of ocular stem cells. Semin Cell Dev Biol. 2007, 18: 805-818.PubMed Pellegrini G, De Luca M, Arsenijevic Y: Towards therapeutic application of ocular stem cells. Semin Cell Dev Biol. 2007, 18: 805-818.PubMed
14.
go back to reference Cha J, Falanga V: Stem cells in cutaneous wound healing. Clin Dermatol. 2007, 25: 73-78.PubMed Cha J, Falanga V: Stem cells in cutaneous wound healing. Clin Dermatol. 2007, 25: 73-78.PubMed
15.
go back to reference Strauer BE, Brehm M, Schannwell CM: The therapeutic potential of stem cells in heart disease. Cell Prolif. 2008, 41: 126-145.PubMed Strauer BE, Brehm M, Schannwell CM: The therapeutic potential of stem cells in heart disease. Cell Prolif. 2008, 41: 126-145.PubMed
16.
go back to reference Wang Z, Lu H, Wang YC, Cong XQ: Human embryonic stem cells and liver diseases: from basic research to future clinical application. J Dig Dis. 2008, 9: 14-19.PubMed Wang Z, Lu H, Wang YC, Cong XQ: Human embryonic stem cells and liver diseases: from basic research to future clinical application. J Dig Dis. 2008, 9: 14-19.PubMed
17.
go back to reference Schulze M, Fändrich F, Ungefroren H, Kremer B: Adult stem cells perspectives in treatment of metabolic diseases. Acta Gastroenterol Belg. 2005, 68: 461-465.PubMed Schulze M, Fändrich F, Ungefroren H, Kremer B: Adult stem cells perspectives in treatment of metabolic diseases. Acta Gastroenterol Belg. 2005, 68: 461-465.PubMed
18.
go back to reference Coutts M, Keirstead HS: Stem cells for the treatment of spinal cord injury. Exp Neurol. 2008, 209: 368-377.PubMed Coutts M, Keirstead HS: Stem cells for the treatment of spinal cord injury. Exp Neurol. 2008, 209: 368-377.PubMed
19.
go back to reference Tseng SS, Lee MA, Reddi AH: Nonunions and the potential of stem cells in fracture- healing. J Bone Joint Surg Am. 2008, 90: 92-98.PubMed Tseng SS, Lee MA, Reddi AH: Nonunions and the potential of stem cells in fracture- healing. J Bone Joint Surg Am. 2008, 90: 92-98.PubMed
20.
go back to reference Cuomo AV, Virk M, Petrigliano F, Morgan EF, Lieberman JR: Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am. 2009, 91: 1073-1083.PubMed Cuomo AV, Virk M, Petrigliano F, Morgan EF, Lieberman JR: Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am. 2009, 91: 1073-1083.PubMed
21.
go back to reference Hope K, Bhatia M: Clonal interrogation of stem cells. Nat Meth Suppl. 2011, 8 (Suppl 4): S36-S40. Hope K, Bhatia M: Clonal interrogation of stem cells. Nat Meth Suppl. 2011, 8 (Suppl 4): S36-S40.
22.
go back to reference Cahan P, Daley GQ: Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol. 2013, 14: 357-368.PubMedCentralPubMed Cahan P, Daley GQ: Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol. 2013, 14: 357-368.PubMedCentralPubMed
23.
go back to reference Kuchina A, Espinar L, Garcia-Ojalvo J, Suel GM: Reversible and noisy progression towards a commitment point enables adaptable and reliable cellular decision-making. PLoS Comput Biol. 2011, 7: e1002273-PubMedCentralPubMed Kuchina A, Espinar L, Garcia-Ojalvo J, Suel GM: Reversible and noisy progression towards a commitment point enables adaptable and reliable cellular decision-making. PLoS Comput Biol. 2011, 7: e1002273-PubMedCentralPubMed
24.
go back to reference Ebben JD, Zorniak M, Clark PA, Kuo JS: Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine. World Neurosurg. 2011, 76 (Suppl 3–4): 270-275.PubMedCentralPubMed Ebben JD, Zorniak M, Clark PA, Kuo JS: Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine. World Neurosurg. 2011, 76 (Suppl 3–4): 270-275.PubMedCentralPubMed
26.
go back to reference Komarova S, Roth J, Alvarez R, Curiel DT, Pereboeva L: Research targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. J of Ovarian Res. 2010, 3: 12- Komarova S, Roth J, Alvarez R, Curiel DT, Pereboeva L: Research targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. J of Ovarian Res. 2010, 3: 12-
27.
go back to reference Ansboro S, Greiser U, Barry F, Murphy M: Strategies for improvement of therapeutic cells: implications for tissue repair. Eur Cells Mater. 2012, 23: 310-319. Ansboro S, Greiser U, Barry F, Murphy M: Strategies for improvement of therapeutic cells: implications for tissue repair. Eur Cells Mater. 2012, 23: 310-319.
28.
go back to reference Kean TJ, Duesler L, Young RG, Dadabayev A, Olenyik A, Penn M, Wagner J, Fink DJ, Caplan AI, Dennis JE: Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell. J Drug Target. 2012, 20 (Suppl 1): 23-32.PubMed Kean TJ, Duesler L, Young RG, Dadabayev A, Olenyik A, Penn M, Wagner J, Fink DJ, Caplan AI, Dennis JE: Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell. J Drug Target. 2012, 20 (Suppl 1): 23-32.PubMed
29.
go back to reference Resina S, Prevot P, Thierry AR: Physico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacy. PLoS One. 2009, 4 (Suppl 6): e6058-PubMedCentralPubMed Resina S, Prevot P, Thierry AR: Physico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacy. PLoS One. 2009, 4 (Suppl 6): e6058-PubMedCentralPubMed
30.
go back to reference Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochem. 1997, 7:36 (1): 66-75. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochem. 1997, 7:36 (1): 66-75.
31.
go back to reference Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J: Gene therapy. Handb Clin Neurol. 2012, 104: 331-338.PubMed Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J: Gene therapy. Handb Clin Neurol. 2012, 104: 331-338.PubMed
32.
go back to reference Burks SR, Ziadloo A, Kim SJ, Nguyen BA, Frank JA: Noninvasive pulsed focused ultrasound allows spatiotemporal control of targeted homing for multiple stem cell types in murine skeletal muscle and the magnitude of cell homing can be increased through repeated applications. Stem Cells. 2013, 31 (Suppl 11): 2551-2560.PubMed Burks SR, Ziadloo A, Kim SJ, Nguyen BA, Frank JA: Noninvasive pulsed focused ultrasound allows spatiotemporal control of targeted homing for multiple stem cell types in murine skeletal muscle and the magnitude of cell homing can be increased through repeated applications. Stem Cells. 2013, 31 (Suppl 11): 2551-2560.PubMed
33.
go back to reference Laflamme MA, Zbinden S, Epstein SE, Murry CE: Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol. 2007, 2: 307-339.PubMed Laflamme MA, Zbinden S, Epstein SE, Murry CE: Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol. 2007, 2: 307-339.PubMed
34.
go back to reference Vaneycken I, D’huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, Caveliers V, Lahoutte T: Immuno-imaging using nanobodies. Curr Opin Biotech. 2011, 22: 877-881.PubMed Vaneycken I, D’huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, Caveliers V, Lahoutte T: Immuno-imaging using nanobodies. Curr Opin Biotech. 2011, 22: 877-881.PubMed
35.
go back to reference Sarkar D, Spencer A, Phillips JA, Zhao W, Schafer S, Spelke DP, Mortensen LJ, Ruiz JP, Vemula PK, Sridharan R, Kumar S, Karnik R, Lin CP, Karp JM: Engineered cell homing. Blood. 2011, 118: e184-e191.PubMedCentralPubMed Sarkar D, Spencer A, Phillips JA, Zhao W, Schafer S, Spelke DP, Mortensen LJ, Ruiz JP, Vemula PK, Sridharan R, Kumar S, Karnik R, Lin CP, Karp JM: Engineered cell homing. Blood. 2011, 118: e184-e191.PubMedCentralPubMed
36.
go back to reference Smart N, Riley PR: The stem cell movement. Circul Res. 2008, 102: 1155-1168. Smart N, Riley PR: The stem cell movement. Circul Res. 2008, 102: 1155-1168.
37.
go back to reference Zhang JJ: Mechanisms of cell therapy for clinical investigations. an urgent need for large-animal models. Circul. 2013, 128: 92-94. Zhang JJ: Mechanisms of cell therapy for clinical investigations. an urgent need for large-animal models. Circul. 2013, 128: 92-94.
38.
go back to reference Gnecchi M, Zhang Z, Ni A, Dzau VJ: Paracrine mechanisms in adult stem cell signaling and therapy. Circul Res. 2008, 103: 1204-1219. Gnecchi M, Zhang Z, Ni A, Dzau VJ: Paracrine mechanisms in adult stem cell signaling and therapy. Circul Res. 2008, 103: 1204-1219.
39.
go back to reference Meirelles LDS, Fontes AM, Covas DT, Caplan AI: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009, 20: 419-427. Meirelles LDS, Fontes AM, Covas DT, Caplan AI: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009, 20: 419-427.
40.
go back to reference Drukker M, Tang C, Ardehali R, Rinkevich Y, Seita J, Lee AS, Mosley AR, Weissman IL, Soen Y: Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells. Nat Biotech. 2012, 30 (Suppl 6): 531-544. Drukker M, Tang C, Ardehali R, Rinkevich Y, Seita J, Lee AS, Mosley AR, Weissman IL, Soen Y: Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells. Nat Biotech. 2012, 30 (Suppl 6): 531-544.
41.
go back to reference Wolff SN: Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transpl. 2002, 29: 545-552. Wolff SN: Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transpl. 2002, 29: 545-552.
42.
go back to reference Zakrzewski JL: Graft failure in allogeneic haematopoietic stem cell transplantation for non-malignant disorders: basics and perspectives. Comp Clin Path. 2003, 12 (Suppl 1): 57-59. Zakrzewski JL: Graft failure in allogeneic haematopoietic stem cell transplantation for non-malignant disorders: basics and perspectives. Comp Clin Path. 2003, 12 (Suppl 1): 57-59.
43.
go back to reference Mattsson J, Ringdén O, Storb R: Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008, 4 (Suppl 1): 165-170. Mattsson J, Ringdén O, Storb R: Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008, 4 (Suppl 1): 165-170.
44.
go back to reference Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, Ringden O: Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl. 2013, 48 (Suppl 4): 616- Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, Ringden O: Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl. 2013, 48 (Suppl 4): 616-
45.
go back to reference Locatelli F, Lucarelli B, Merli P: Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother. 2014, 15 (Suppl 1): 23-36.PubMed Locatelli F, Lucarelli B, Merli P: Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother. 2014, 15 (Suppl 1): 23-36.PubMed
46.
go back to reference Sanz-Ruiz R, Ibanes EG, Arrranz AV, Santos MEF, Fernandez PLS, Fernandez-Aviles F: Phases I-III clinical trials using adult stem cells.Stem cells Intern 2010, 1–12., Sanz-Ruiz R, Ibanes EG, Arrranz AV, Santos MEF, Fernandez PLS, Fernandez-Aviles F: Phases I-III clinical trials using adult stem cells.Stem cells Intern 2010, 1–12.,
47.
go back to reference Tara M, Herrick RPM: Tapping the potential of fixed-dose combinations. Nat Rev Drug Disc. 2007, 6: 513-514. Tara M, Herrick RPM: Tapping the potential of fixed-dose combinations. Nat Rev Drug Disc. 2007, 6: 513-514.
48.
go back to reference Mocanu MM, Yellon DM: PTEN, the Achilles’ heel of myocardial ischemia/reperfusion injury?. Br J Pharmacol. 2007, 150: 833-838.PubMedCentralPubMed Mocanu MM, Yellon DM: PTEN, the Achilles’ heel of myocardial ischemia/reperfusion injury?. Br J Pharmacol. 2007, 150: 833-838.PubMedCentralPubMed
49.
go back to reference Ye Y, Lin Y, Atar S, Huang MH, Perez-Polo JR, Uretsky BF, Birnbaum Y: Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol. 2006, 291: 1158-1169. Ye Y, Lin Y, Atar S, Huang MH, Perez-Polo JR, Uretsky BF, Birnbaum Y: Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol. 2006, 291: 1158-1169.
50.
go back to reference Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Barry FU, Yochai Birnbaum MD: Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with lowdose atorvastatin. Cardiovasc Drugs Ther. 2006, 20: 27-36.PubMed Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Barry FU, Yochai Birnbaum MD: Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with lowdose atorvastatin. Cardiovasc Drugs Ther. 2006, 20: 27-36.PubMed
51.
go back to reference Foubert P, Matrone G, Souttou B, Lere’-De’An C, Barateau V, Plouet J, Le Ricousse-Roussanne S, Levy BI, Silvestre J, Tobelem G: Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy. Circ Res. 2008, 103: 751-760.PubMed Foubert P, Matrone G, Souttou B, Lere’-De’An C, Barateau V, Plouet J, Le Ricousse-Roussanne S, Levy BI, Silvestre J, Tobelem G: Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy. Circ Res. 2008, 103: 751-760.PubMed
52.
go back to reference Yamahara K, Sone M, Itoh H, Yamashita JK, Yurugi-Kobayashi T, Homma K, Chao T, Miyashita K, Park K, Oyamada N, Sawada N, Taura D, Fukunaga Y, Tamura N, Nakao K: Augmentation of neovascularizaiton in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells. PLoS One. 2008, 3: e1666-PubMedCentralPubMed Yamahara K, Sone M, Itoh H, Yamashita JK, Yurugi-Kobayashi T, Homma K, Chao T, Miyashita K, Park K, Oyamada N, Sawada N, Taura D, Fukunaga Y, Tamura N, Nakao K: Augmentation of neovascularizaiton in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells. PLoS One. 2008, 3: e1666-PubMedCentralPubMed
53.
go back to reference Kanathezhath B, Walters MC: Umbilical cord blood transplantation for thalassemia major. Hematol Oncol Clin North Am. 2010, 24: 1165-1177.PubMed Kanathezhath B, Walters MC: Umbilical cord blood transplantation for thalassemia major. Hematol Oncol Clin North Am. 2010, 24: 1165-1177.PubMed
54.
go back to reference Madureira AB, Eapen M, Locatelli F, Teira P, Zhang MJ, Davies SM, Picardi A, Woolfrey A, Chan KW, Socie G, Vora A, Bertrand Y, Sales-Bonfim CM, Gluckman E, Niemeyer C, Rocha V: Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. Leukemia. 2011, 25: 449-454.PubMedCentralPubMed Madureira AB, Eapen M, Locatelli F, Teira P, Zhang MJ, Davies SM, Picardi A, Woolfrey A, Chan KW, Socie G, Vora A, Bertrand Y, Sales-Bonfim CM, Gluckman E, Niemeyer C, Rocha V: Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. Leukemia. 2011, 25: 449-454.PubMedCentralPubMed
55.
go back to reference Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ: Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: Umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplan. 2012, 47: 494-498. Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ: Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: Umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplan. 2012, 47: 494-498.
56.
go back to reference Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG: Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplan. 2011, 17: 1327-1334. Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG: Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplan. 2011, 17: 1327-1334.
57.
go back to reference Carrancio S, Romo C, Ramos T, Lopez-Holgado N, Muntion S, Prins HJ, Martens AC, Brinon JG, Miguel JFS, del Canizo MC, Sanchez-Guijo F: Effects of MSC coadministration and route of delivery on cord blood hematopiectic stem cell engraftment. Cell Transplan. 2013, 22: 1171-1183. Carrancio S, Romo C, Ramos T, Lopez-Holgado N, Muntion S, Prins HJ, Martens AC, Brinon JG, Miguel JFS, del Canizo MC, Sanchez-Guijo F: Effects of MSC coadministration and route of delivery on cord blood hematopiectic stem cell engraftment. Cell Transplan. 2013, 22: 1171-1183.
58.
go back to reference Kirpatovskii VI, Kazachenko V, Yanenko EK, Kovalenko EA, Golovanov SA: Enhancement of the anti-ischemic kidney resistance by adaptive hypoxic preconditioning and drug therapy. Bullet Exp Biol Med. 1999, 127: 278-281. Kirpatovskii VI, Kazachenko V, Yanenko EK, Kovalenko EA, Golovanov SA: Enhancement of the anti-ischemic kidney resistance by adaptive hypoxic preconditioning and drug therapy. Bullet Exp Biol Med. 1999, 127: 278-281.
59.
go back to reference Kato T, Yoshimoto N: Ischemic preconditioning and outcomes after angioplasty: effects of drug therapy. Drugs. 2003, 63: 133-138.PubMed Kato T, Yoshimoto N: Ischemic preconditioning and outcomes after angioplasty: effects of drug therapy. Drugs. 2003, 63: 133-138.PubMed
60.
go back to reference Diaz Z, Assaraf MI, Miller WHJ, Schipper HM: Astroglial cytoprotection by erythropoietinpre-conditioning: implications for ischemic and degenerative CNS disorders. J Neurochem. 2005, 93: 392-402.PubMed Diaz Z, Assaraf MI, Miller WHJ, Schipper HM: Astroglial cytoprotection by erythropoietinpre-conditioning: implications for ischemic and degenerative CNS disorders. J Neurochem. 2005, 93: 392-402.PubMed
62.
go back to reference Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, Iekushi K, Dimmeler S, Granja TF, Boehm O, Claycomb WC, Zacharowski K: Preconditioning by toll-like receptor 2 agonist pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med. 2010, 38: 903-909.PubMed Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, Iekushi K, Dimmeler S, Granja TF, Boehm O, Claycomb WC, Zacharowski K: Preconditioning by toll-like receptor 2 agonist pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med. 2010, 38: 903-909.PubMed
63.
go back to reference McNally SJ, Harrison EM, Wigmore SJ: Ethical considerations in the application of preconditioning to solid organ transplantation. J Med Ethics. 2005, 31: 631-634.PubMedCentralPubMed McNally SJ, Harrison EM, Wigmore SJ: Ethical considerations in the application of preconditioning to solid organ transplantation. J Med Ethics. 2005, 31: 631-634.PubMedCentralPubMed
64.
go back to reference Haider HK, Ashraf M: Preconditioning and stem cell survival. J Cardiovasc Transl Res. 2010, 3: 89-102.PubMed Haider HK, Ashraf M: Preconditioning and stem cell survival. J Cardiovasc Transl Res. 2010, 3: 89-102.PubMed
65.
go back to reference Cai H, Zhang Z, Yang GY: Preconditioned Stem Cells: a Promising Strategy for Cell-Based Ischemic Stroke Therapy. Curr Drug Targets. 2014, 15 (8): 771-779.PubMed Cai H, Zhang Z, Yang GY: Preconditioned Stem Cells: a Promising Strategy for Cell-Based Ischemic Stroke Therapy. Curr Drug Targets. 2014, 15 (8): 771-779.PubMed
66.
go back to reference Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009, 4 (Suppl 6): 581- Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009, 4 (Suppl 6): 581-
67.
go back to reference Moschidou D, Mukherjee S, Blundell MP, Drews K, Jones GN, Abdulrazzak H, Nowakowska B, Phoolchund A, Lay K, Ramasamy TS, Cananzi M, Nettersheim D, Sullivan M, Frost J, Moore G, Vermeesch JR, Fisk NM, Thrasher AJ, Atala A, Adjaye J, Schorle H, Coppi PD, Guillot PV: Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Mol Therapy. 2012, 20 (10): 1953-1967. Moschidou D, Mukherjee S, Blundell MP, Drews K, Jones GN, Abdulrazzak H, Nowakowska B, Phoolchund A, Lay K, Ramasamy TS, Cananzi M, Nettersheim D, Sullivan M, Frost J, Moore G, Vermeesch JR, Fisk NM, Thrasher AJ, Atala A, Adjaye J, Schorle H, Coppi PD, Guillot PV: Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Mol Therapy. 2012, 20 (10): 1953-1967.
68.
go back to reference Haider KH, Ashraf M: Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol Transl Sci. 2012, 111: 323-356.PubMed Haider KH, Ashraf M: Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol Transl Sci. 2012, 111: 323-356.PubMed
69.
go back to reference Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, Takahashi JB, Nishikawa S, Nishikawa S, Muguruma K, Sasai Y: A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotech. 2007, 25: 681-686. Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, Takahashi JB, Nishikawa S, Nishikawa S, Muguruma K, Sasai Y: A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotech. 2007, 25: 681-686.
70.
go back to reference Ramasamy TS, Yu JSL, Selden C, Hodgson H, Cui W: Application of three-dimensional culture conditions to human embryonic stem cell-derived definitive endoderm cells enhances hepatocyte differentiation and functionality. Tissue Eng Part A. 2013, 19 (Suppl 3–4): 360-367.PubMed Ramasamy TS, Yu JSL, Selden C, Hodgson H, Cui W: Application of three-dimensional culture conditions to human embryonic stem cell-derived definitive endoderm cells enhances hepatocyte differentiation and functionality. Tissue Eng Part A. 2013, 19 (Suppl 3–4): 360-367.PubMed
71.
go back to reference Jeremy LH, Yue W, Abarbanell MA, Brent RW, Jiangning T, Daniel RM: Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell mediated cardioprotection. Shock. 2010, 33: 24-30. Jeremy LH, Yue W, Abarbanell MA, Brent RW, Jiangning T, Daniel RM: Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell mediated cardioprotection. Shock. 2010, 33: 24-30.
72.
go back to reference Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang J, Wei L: Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008, 135: 799-808.PubMed Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang J, Wei L: Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008, 135: 799-808.PubMed
73.
go back to reference Pasha Z, Wang Y, Sheikh R, Zhang D, Tiemin Zhao T, Ashraf M: Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res. 2008, 77: 134-142.PubMed Pasha Z, Wang Y, Sheikh R, Zhang D, Tiemin Zhao T, Ashraf M: Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res. 2008, 77: 134-142.PubMed
74.
go back to reference Carriere A, Ebrahimian TG, Dehez S, Auge N, Joffre C, Andre M, Arnal S, Duriez M, Barreau C, Arnaud E, Fernandez Y, Planat-Benard V, Lévy B, Pénicaud L, Silvestre JS, Casteilla L: Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy. Arterioscler Thromb Vasc Biol. 2009, 29: 1093-1099.PubMed Carriere A, Ebrahimian TG, Dehez S, Auge N, Joffre C, Andre M, Arnal S, Duriez M, Barreau C, Arnaud E, Fernandez Y, Planat-Benard V, Lévy B, Pénicaud L, Silvestre JS, Casteilla L: Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy. Arterioscler Thromb Vasc Biol. 2009, 29: 1093-1099.PubMed
75.
go back to reference Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, Rivera BK, Sun BC, Hideg K, Kuppusamy P: Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-Trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacolo Exp Ther. 2009, 329: 543-550. Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, Rivera BK, Sun BC, Hideg K, Kuppusamy P: Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-Trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacolo Exp Ther. 2009, 329: 543-550.
76.
go back to reference Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ: Therapeutic cell engineering using surface-conjugated synthetic nanoparticles. Nat Med. 2010, 16: 1035-1041.PubMedCentralPubMed Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ: Therapeutic cell engineering using surface-conjugated synthetic nanoparticles. Nat Med. 2010, 16: 1035-1041.PubMedCentralPubMed
77.
go back to reference Mamidi MK, Pal R, Govindasamy V, Zakaria Z, Bhonde R: Treat the graft to improve the regeneration ability of the host. Med Hyp. 2011, 76: 599-601. Mamidi MK, Pal R, Govindasamy V, Zakaria Z, Bhonde R: Treat the graft to improve the regeneration ability of the host. Med Hyp. 2011, 76: 599-601.
78.
79.
go back to reference Kim SW, Kim HW, Huang W, Okada M, Welge JA, Wang Y, Ashraf M: Cardiac stem cells with electrical stimulation improve ischaemic heart function through regulation of connective tissue growth factor and miR-378. Cardiovascular Res. 2013, 100 (Suppl 2): 241-251. Kim SW, Kim HW, Huang W, Okada M, Welge JA, Wang Y, Ashraf M: Cardiac stem cells with electrical stimulation improve ischaemic heart function through regulation of connective tissue growth factor and miR-378. Cardiovascular Res. 2013, 100 (Suppl 2): 241-251.
80.
go back to reference Jaderstad J, Brismar H, Herlenius E: Hypoxia preconditioning increases gap-junctional graft and host communication. Neuro-report. 2010, 21: 1126-1132. Jaderstad J, Brismar H, Herlenius E: Hypoxia preconditioning increases gap-junctional graft and host communication. Neuro-report. 2010, 21: 1126-1132.
81.
go back to reference Lau TT, Wang DA: Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther. 2011, 11 (Suppl 2): 189-197.PubMed Lau TT, Wang DA: Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther. 2011, 11 (Suppl 2): 189-197.PubMed
82.
go back to reference Jones J, Marian D, Weich E, Engl T, Wedel S, Relja B, Jonas D, Blaheta RA: CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res. 2007, 313 (Suppl 19): 4051-4065.PubMed Jones J, Marian D, Weich E, Engl T, Wedel S, Relja B, Jonas D, Blaheta RA: CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res. 2007, 313 (Suppl 19): 4051-4065.PubMed
83.
go back to reference Jenkins AJ, Cone EJ: Pharmacokinetics: drug absorption, distribution and elimination. Drug Abuse Handbook. Edited by: Karch SB. 1998, Boca Rato’n, FL, CRC Press, 151-201. Jenkins AJ, Cone EJ: Pharmacokinetics: drug absorption, distribution and elimination. Drug Abuse Handbook. Edited by: Karch SB. 1998, Boca Rato’n, FL, CRC Press, 151-201.
84.
go back to reference Brunskill SJ, Hyde CJ, Doree CJ, Suzanne M, Watt SM, Martin-Rendon E: Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrowderived cell therapy for ischaemic heart disease. Europ J Heart Fail. 2009, 11: 887-896. Brunskill SJ, Hyde CJ, Doree CJ, Suzanne M, Watt SM, Martin-Rendon E: Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrowderived cell therapy for ischaemic heart disease. Europ J Heart Fail. 2009, 11: 887-896.
85.
go back to reference Zonta S, De Martino M, Bedino G, Piotti G, Rampino T, Gregorini M, Frassoni F, Dal Canton A, Dionigi P, Alessiani M: Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial?. Transplant Proc. 2010, 42: 1336-1340.PubMed Zonta S, De Martino M, Bedino G, Piotti G, Rampino T, Gregorini M, Frassoni F, Dal Canton A, Dionigi P, Alessiani M: Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial?. Transplant Proc. 2010, 42: 1336-1340.PubMed
86.
go back to reference Fernandez-Aviles F, San Roman JA, Garcia-Frade J, Fernandez ME, Penarrubia MJ, de laFuente L, Gómez-Bueno M, Cantalapiedra A, Fernández J, Gutierrez O, Sánchez PL, Hernández C, Sanz R, García-Sancho J, Sánchez A: Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res. 2004, 95: 742-748.PubMed Fernandez-Aviles F, San Roman JA, Garcia-Frade J, Fernandez ME, Penarrubia MJ, de laFuente L, Gómez-Bueno M, Cantalapiedra A, Fernández J, Gutierrez O, Sánchez PL, Hernández C, Sanz R, García-Sancho J, Sánchez A: Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res. 2004, 95: 742-748.PubMed
87.
go back to reference Ott HC, McCue J, Taylor DA: Cell-based cardiovascular repair-the hurdles and the opportunities. Basic Res Cardiol. 2005, 100: 504-517.PubMed Ott HC, McCue J, Taylor DA: Cell-based cardiovascular repair-the hurdles and the opportunities. Basic Res Cardiol. 2005, 100: 504-517.PubMed
88.
go back to reference Fuchs S, Kornowski R, Weisz G, Satler LF, Smits PC, Okubagzi P, Baffour R, Aggarwal A, Weissman NJ, Cerqueira M, Waksman R, Serrruys P, Battler A, Moses JW, Leon MB, Epstein SE: Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol. 2006, 97: 823-829.PubMed Fuchs S, Kornowski R, Weisz G, Satler LF, Smits PC, Okubagzi P, Baffour R, Aggarwal A, Weissman NJ, Cerqueira M, Waksman R, Serrruys P, Battler A, Moses JW, Leon MB, Epstein SE: Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol. 2006, 97: 823-829.PubMed
89.
go back to reference Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T: Catheterbased delivery of cells to the heart. Nat Clin Pract. 2006, 3: S57-S64. Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T: Catheterbased delivery of cells to the heart. Nat Clin Pract. 2006, 3: S57-S64.
90.
go back to reference Dimmeler S, Burchfield J, Zeiher AM: Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008, 28: 208-216.PubMed Dimmeler S, Burchfield J, Zeiher AM: Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008, 28: 208-216.PubMed
91.
go back to reference Willing E, Garbuzova-Davis S, Sanberg PR, Saporta S: Routes of stem cell administration in the adult rodent. Methods Mol Biol. 2008, 438: 383-401.PubMed Willing E, Garbuzova-Davis S, Sanberg PR, Saporta S: Routes of stem cell administration in the adult rodent. Methods Mol Biol. 2008, 438: 383-401.PubMed
92.
go back to reference Cindy TJ, Velthoven V, kaVelaars A, van Bel F, Heijnen CJ: Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res. 2010, 68: 419-422. Cindy TJ, Velthoven V, kaVelaars A, van Bel F, Heijnen CJ: Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res. 2010, 68: 419-422.
93.
go back to reference Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, Katakowski M, Zhang LJ, Lu M, Janakiraman N, Chopp M: Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology. 2002, 59: 514-523.PubMed Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, Katakowski M, Zhang LJ, Lu M, Janakiraman N, Chopp M: Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology. 2002, 59: 514-523.PubMed
94.
go back to reference Sykova E, Homola A, Mazanec R, Lachmann H, Konradova SL, Kobylka P, Pádr R, Neuwirth J, Komrska V, Vávra V, Stulík J, Bojar M: Autologous bone marrow transplantation in patients with sub acute and chronic spinal cord injury. Cell Transplant. 2006, 15: 675-687.PubMed Sykova E, Homola A, Mazanec R, Lachmann H, Konradova SL, Kobylka P, Pádr R, Neuwirth J, Komrska V, Vávra V, Stulík J, Bojar M: Autologous bone marrow transplantation in patients with sub acute and chronic spinal cord injury. Cell Transplant. 2006, 15: 675-687.PubMed
95.
go back to reference Paul C, Samdani AF, Betz RR, Fischer I, Birgit Neuhuber B: Grafting of human bone marrow stromal cells into spinal cord injury: A comparison of delivery methods. Spine (Phila Pa 1976). 2009, 34: 328-334. Paul C, Samdani AF, Betz RR, Fischer I, Birgit Neuhuber B: Grafting of human bone marrow stromal cells into spinal cord injury: A comparison of delivery methods. Spine (Phila Pa 1976). 2009, 34: 328-334.
96.
go back to reference Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002, 106: 1913-1918.PubMed Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002, 106: 1913-1918.PubMed
97.
go back to reference Moscoso I, Barallobre J, de Ilarduya ÓM, Añón P, Fraga M, Calviño R, Aldama G, Doménech N: Analysis of different routes of administration of heterologous 5-Azacytidine-treated mesenchymal stem cells in a porcine model of myocardial infarction. Transplant Proc. 2009, 41: 2273-2275.PubMed Moscoso I, Barallobre J, de Ilarduya ÓM, Añón P, Fraga M, Calviño R, Aldama G, Doménech N: Analysis of different routes of administration of heterologous 5-Azacytidine-treated mesenchymal stem cells in a porcine model of myocardial infarction. Transplant Proc. 2009, 41: 2273-2275.PubMed
98.
go back to reference Rigol MR, Solanes N, Farre J, Roura S, Roque M, Berruezo A, Bellera N, Novensà L, Tamborero D, Prat-Vidal C, Huzman MA, Batlle M, Hoefsloot M, Sitges M, Ramírez J, Dantas AP, Merino A, Sanz G, Brugada J, Bayés-Genís A, Heras M: Effects of adipose tissue-derived stem cell therapy after myocardial infarction: impact of the route of administration. J Card Fail. 2010, 16: 357-366.PubMed Rigol MR, Solanes N, Farre J, Roura S, Roque M, Berruezo A, Bellera N, Novensà L, Tamborero D, Prat-Vidal C, Huzman MA, Batlle M, Hoefsloot M, Sitges M, Ramírez J, Dantas AP, Merino A, Sanz G, Brugada J, Bayés-Genís A, Heras M: Effects of adipose tissue-derived stem cell therapy after myocardial infarction: impact of the route of administration. J Card Fail. 2010, 16: 357-366.PubMed
99.
go back to reference Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC: The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011, 18: 488-495.PubMedCentralPubMed Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC: The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011, 18: 488-495.PubMedCentralPubMed
100.
go back to reference Geffner LF, Santacruz P, Izurieta M, Flor L, Maldonado B, Auad AH, Montenegro X, Gonzalez R, Silva F: Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008, 17: 1277-1293.PubMed Geffner LF, Santacruz P, Izurieta M, Flor L, Maldonado B, Auad AH, Montenegro X, Gonzalez R, Silva F: Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008, 17: 1277-1293.PubMed
101.
go back to reference Strauer BE, Kornowski R: Stem cell therapy in perspective. Circulation. 2003, 107: 929-934.PubMed Strauer BE, Kornowski R: Stem cell therapy in perspective. Circulation. 2003, 107: 929-934.PubMed
102.
go back to reference Johanson CE, Uhlenhuth EH: Drug preferences in humans. Fed Proc. 1982, 41: 228-233.PubMed Johanson CE, Uhlenhuth EH: Drug preferences in humans. Fed Proc. 1982, 41: 228-233.PubMed
103.
go back to reference de wit H, Uhlenhuth EH, Johanson CE: Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend. 1986, 16: 341-360.PubMed de wit H, Uhlenhuth EH, Johanson CE: Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend. 1986, 16: 341-360.PubMed
104.
go back to reference Thurmann PA: Gender-related differences in pharmacokinetics and pharmocodynamics. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005, 48: 536-540.PubMed Thurmann PA: Gender-related differences in pharmacokinetics and pharmocodynamics. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005, 48: 536-540.PubMed
105.
go back to reference Soldin OP, Mattison DR: Sex differnces in pharmacokinetics and pharmocodynamics. Clin Pharmocokinet. 2009, 48: 143-157. Soldin OP, Mattison DR: Sex differnces in pharmacokinetics and pharmocodynamics. Clin Pharmocokinet. 2009, 48: 143-157.
106.
go back to reference Hughes DA, Aronson JK: A systematic review and empirical analysis of the relation between dose and duration of drug action. J Clin Pharmacol. 2010, 50: 17-26.PubMed Hughes DA, Aronson JK: A systematic review and empirical analysis of the relation between dose and duration of drug action. J Clin Pharmacol. 2010, 50: 17-26.PubMed
107.
go back to reference Varrassi G, Marinangeli F, Agro F, Aloe L, De Nicola A, Giunta F, Ischia S, Ballabio M, Stefanini S: A double-blinded evaluation of propacetamol versus ketorolac in combination with patient controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery. Anesth Analg. 1999, 88: 611-616.PubMed Varrassi G, Marinangeli F, Agro F, Aloe L, De Nicola A, Giunta F, Ischia S, Ballabio M, Stefanini S: A double-blinded evaluation of propacetamol versus ketorolac in combination with patient controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery. Anesth Analg. 1999, 88: 611-616.PubMed
108.
go back to reference Struys MMRF, Sahinovic M, Lichtenbelt BJ, Vereecke HEM, Absalom AR: Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts. Brit J Anaesth. 2011, 107: 1-10. Struys MMRF, Sahinovic M, Lichtenbelt BJ, Vereecke HEM, Absalom AR: Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts. Brit J Anaesth. 2011, 107: 1-10.
109.
go back to reference Bartmann C, Rohde E, Schallmoser K, Pürstner P, Lanzer G, Linkesch W, Strunk D: Two steps to functional mesenchymal stromal cells for clinical application. Transfusion. 2007, 47: 1426-1435.PubMed Bartmann C, Rohde E, Schallmoser K, Pürstner P, Lanzer G, Linkesch W, Strunk D: Two steps to functional mesenchymal stromal cells for clinical application. Transfusion. 2007, 47: 1426-1435.PubMed
110.
go back to reference Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A: Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol. 2010, 227: 185-189.PubMed Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A: Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol. 2010, 227: 185-189.PubMed
111.
go back to reference Kishk NA, Gabr H, Hamdy S, Afifi L, Abokresha N, Mahmoud H, Wafaie A, Bilal D: Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair. 2010, 24: 702-708.PubMed Kishk NA, Gabr H, Hamdy S, Afifi L, Abokresha N, Mahmoud H, Wafaie A, Bilal D: Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair. 2010, 24: 702-708.PubMed
112.
go back to reference Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L: Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010, 69: 1423-1429.PubMed Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L: Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010, 69: 1423-1429.PubMed
113.
go back to reference Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Reisman MA, Schaer GL, Sherman W: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction. J Am Coll Cardiol. 2009, 54 (24): 2277-2286.PubMedCentralPubMed Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Reisman MA, Schaer GL, Sherman W: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction. J Am Coll Cardiol. 2009, 54 (24): 2277-2286.PubMedCentralPubMed
114.
go back to reference Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Brynes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A: Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012, 308: 2369-2379.PubMed Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Brynes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A: Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012, 308: 2369-2379.PubMed
117.
go back to reference Hess DC, Sila CA, Furlan AJ, Wechsler LR, Switzer JA, Mays RW: A double-blind placebo- controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke. 2014, 9 (3): 381-386.PubMed Hess DC, Sila CA, Furlan AJ, Wechsler LR, Switzer JA, Mays RW: A double-blind placebo- controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke. 2014, 9 (3): 381-386.PubMed
119.
go back to reference Mason C, Mason J, Culme-Seymour EJ, Bonfiglio GA, Reeve BC: Cell Therapy Companies Make Strong Progress from October 2012 to March 2013 Amid Mixed Stock Market Sentiment. Cell Stem Cell. 2013, 12: 644-647.PubMed Mason C, Mason J, Culme-Seymour EJ, Bonfiglio GA, Reeve BC: Cell Therapy Companies Make Strong Progress from October 2012 to March 2013 Amid Mixed Stock Market Sentiment. Cell Stem Cell. 2013, 12: 644-647.PubMed
120.
go back to reference Ma T: Mesenchymal stem cells; cell therapy; cell expansion and processing. World J of Stem Cells. 2010, 2: 13-17. Ma T: Mesenchymal stem cells; cell therapy; cell expansion and processing. World J of Stem Cells. 2010, 2: 13-17.
121.
go back to reference Ledford KJ, Zeigler F, Bartel RL: Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages. Stem Cell Res Ther. 2013, 4: 134-PubMedCentralPubMed Ledford KJ, Zeigler F, Bartel RL: Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages. Stem Cell Res Ther. 2013, 4: 134-PubMedCentralPubMed
122.
go back to reference Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R: Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012, 379 (9817): 713-720.PubMed Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R: Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012, 379 (9817): 713-720.PubMed
123.
go back to reference Vaes B, Van’t Hof W, Deans RJ, Pinxteren J: Application of MultiStem allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol. 2012, 3: 345-PubMedCentralPubMed Vaes B, Van’t Hof W, Deans RJ, Pinxteren J: Application of MultiStem allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol. 2012, 3: 345-PubMedCentralPubMed
127.
go back to reference Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF: Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med. 2010, 363: 411-422.PubMed Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF: Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med. 2010, 363: 411-422.PubMed
141.
go back to reference Murphy MB, Moncivais K, Caplan AI: Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013, 45 (e54): 1-16. Murphy MB, Moncivais K, Caplan AI: Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013, 45 (e54): 1-16.
142.
go back to reference Haack-Sørensen M, Friis T, Mathiasen AB, Jørgensen E, Hansen L, Dickmeiss E, Ekblond A, Kastrup J: Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up. Cell Transplant. 2013, 22: 521-528.PubMed Haack-Sørensen M, Friis T, Mathiasen AB, Jørgensen E, Hansen L, Dickmeiss E, Ekblond A, Kastrup J: Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up. Cell Transplant. 2013, 22: 521-528.PubMed
143.
go back to reference Chen L, Tredget EE, Wu PYG, Wu Y: Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008, 3: e1886-PubMedCentralPubMed Chen L, Tredget EE, Wu PYG, Wu Y: Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008, 3: e1886-PubMedCentralPubMed
144.
go back to reference Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, Shrayer D, Carson P: Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007, 13: 1299-1312.PubMed Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, Shrayer D, Carson P: Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007, 13: 1299-1312.PubMed
145.
go back to reference Bey E, Prat M, Duhamel P, Benderitter M, Brachet M, Trompier F, Battaglini P, Ernoul I, Boutin L, Gourven M, Tissedre F, Crea S, Mansour CA, de Revel T, Carsin H, Gourmelon P, Lataillade JJ: Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations. Wound Repair Regen. 2010, 18: 50-58.PubMed Bey E, Prat M, Duhamel P, Benderitter M, Brachet M, Trompier F, Battaglini P, Ernoul I, Boutin L, Gourven M, Tissedre F, Crea S, Mansour CA, de Revel T, Carsin H, Gourmelon P, Lataillade JJ: Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations. Wound Repair Regen. 2010, 18: 50-58.PubMed
146.
go back to reference Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiura M, Ideno H, Shimada A, Nifuji A, Abe M: Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2014, 494: 100-105. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiura M, Ideno H, Shimada A, Nifuji A, Abe M: Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2014, 494: 100-105.
147.
148.
go back to reference Abbasalizadeh S, Baharvand H: Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotech Adv. 2013, 31 (8): 1600-1623. Abbasalizadeh S, Baharvand H: Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotech Adv. 2013, 31 (8): 1600-1623.
149.
go back to reference Ma Q, Lu AYH: Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. Pharmacol Rev. 2011, 63: 437-459.PubMed Ma Q, Lu AYH: Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. Pharmacol Rev. 2011, 63: 437-459.PubMed
Metadata
Title
Advancing stem cell therapy from bench to bedside: lessons from drug therapies
Authors
Thekkeparambil Chandrabose Srijaya
Thamil Selvee Ramasamy
Noor Hayaty Abu Kasim
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-014-0243-9

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.